A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months
Public ClinicalTrials.gov record NCT05743881. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to assess the safety and immunogenicity of mRNA-1365, an mRNA vaccine targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) and mRNA-1345, an mRNA vaccine targeting RSV, in participants aged 5 months to \<24 months.
Study identification
- NCT ID
- NCT05743881
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 186 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 5 Months to 24 Months
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 15, 2023 (Actual)
- Primary completion
- Aug 31, 2029 (Estimated)
- Completion
- Aug 31, 2029 (Estimated)
- Last update posted
- Jun 26, 2026
2023 – 2029
United States locations
- U.S. sites
- 12
- U.S. states
- 9
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Matrix Clinical Research | Los Angeles | California | 90057 | — |
| Meridian Clinical Research | Washington D.C. | District of Columbia | 20016 | — |
| DM Clinical Research- River Forest | Melrose Park | Illinois | 60160 | — |
| MedPharmics - Platinum - PPDS | Lafayette | Louisiana | 70508 | — |
| Duke Vaccine and Trials Unit | Durham | North Carolina | 27703 | — |
| Velocity Clinical Research - Providence | Providence | Rhode Island | 02886 | — |
| Palmetto Pediatrics, PA | North Charleston | South Carolina | 29406-9170 | — |
| Vanderbilt Vaccine Research Program | Nashville | Tennessee | 37232 | — |
| CyFair | Houston | Texas | 77065 | — |
| Pediatric Associates | Houston | Texas | 77087 | — |
| Village Pediatrics | Plano | Texas | 75024 | — |
| Pediatric Center | Richmond | Texas | 77469 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05743881, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 26, 2026 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05743881 live on ClinicalTrials.gov.